Medical - Devices
Compare Stocks
5 / 10Stock Comparison
PEN vs INVA vs ISRG vs PRGO vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Instruments & Supplies
Drug Manufacturers - Specialty & Generic
Medical - Devices
PEN vs INVA vs ISRG vs PRGO vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Medical - Devices |
| Market Cap | $12.67B | $1.69B | $159.85B | $1.62B | $109.33B |
| Revenue (TTM) | $1.45B | $424M | $10.58B | $4.18B | $25.12B |
| Net Income (TTM) | $171M | $504M | $2.98B | $-1.82B | $3.25B |
| Gross Margin | 67.4% | 76.2% | 66.3% | 34.2% | 63.5% |
| Operating Margin | 12.9% | 14.8% | 30.5% | -4.1% | 22.4% |
| Forward P/E | 65.8x | 7.3x | 43.3x | 5.5x | 19.1x |
| Total Debt | $220M | $269M | $303M | $3.97B | $14.86B |
| Cash & Equiv. | $187M | $551M | $3.37B | $532M | $4.01B |
PEN vs INVA vs ISRG vs PRGO vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Penumbra, Inc. (PEN) | 100 | 186.9 | +86.9% |
| Innoviva, Inc. (INVA) | 100 | 163.9 | +63.9% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| Stryker Corporation (SYK) | 100 | 145.8 | +45.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PEN vs INVA vs ISRG vs PRGO vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PEN lags the leaders in this set but could rank higher in a more targeted comparison.
INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.11, Low D/E 22.9%, current ratio 14.64x
- PEG 0.71 vs ISRG's 1.99
- Beta 0.11, current ratio 14.64x
- Lower P/E (7.3x vs 19.1x), PEG 0.71 vs 1.28
ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs PEN's 5.0%
- 20.5% revenue growth vs PRGO's -2.8%
PRGO ranks third and is worth considering specifically for dividends.
- 9.8% yield, 10-year raise streak, vs SYK's 1.2%, (3 stocks pay no dividend)
SYK is the clearest fit if your priority is income & stability.
- Dividend streak 34 yrs, beta 0.52, yield 1.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (7.3x vs 19.1x), PEG 0.71 vs 1.28 | |
| Quality / Margins | 118.9% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.11 vs PRGO's 1.21, lower leverage | |
| Dividends | 9.8% yield, 10-year raise streak, vs SYK's 1.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +23.2% vs PRGO's -52.0% | |
| Efficiency (ROA) | 32.4% ROA vs PRGO's -19.8%, ROIC 14.2% vs 3.7% |
PEN vs INVA vs ISRG vs PRGO vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PEN vs INVA vs ISRG vs PRGO vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 3 of 6 categories
PRGO leads 1 • ISRG leads 1 • PEN leads 0 • SYK leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 59.2x INVA's $424M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $424M | $10.6B | $4.2B | $25.1B |
| EBITDAEarnings before interest/tax | $200M | $86M | $3.8B | $58M | $6.3B |
| Net IncomeAfter-tax profit | $171M | $504M | $3.0B | -$1.8B | $3.2B |
| Free Cash FlowCash after capex | $213M | $181M | $2.8B | $108M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +67.4% | +76.2% | +66.3% | +34.2% | +63.5% |
| Operating MarginEBIT ÷ Revenue | +12.9% | +14.8% | +30.5% | -4.1% | +22.4% |
| Net MarginNet income ÷ Revenue | +11.8% | +118.9% | +28.2% | -43.5% | +12.9% |
| FCF MarginFCF ÷ Revenue | +14.6% | +42.6% | +26.8% | +2.6% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.6% | +10.6% | +23.0% | -7.2% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -18.0% | +4.0% | +18.8% | -56.4% | +56.0% |
Valuation Metrics
PRGO leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 90% valuation discount to PEN's 71.3x P/E. Adjusting for growth (PEG ratio), INVA offers better value at 0.67x vs ISRG's 2.63x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12.7B | $1.7B | $159.8B | $1.6B | $109.3B |
| Enterprise ValueMkt cap + debt − cash | $12.7B | $1.4B | $156.8B | $5.1B | $120.2B |
| Trailing P/EPrice ÷ TTM EPS | 71.29x | 6.94x | 57.19x | -1.14x | 33.98x |
| Forward P/EPrice ÷ next-FY EPS est. | 65.80x | 7.31x | 43.35x | 5.53x | 19.06x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x | 2.63x | — | 2.29x |
| EV / EBITDAEnterprise value multiple | 61.47x | 6.90x | 43.28x | 7.43x | 19.76x |
| Price / SalesMarket cap ÷ Revenue | 9.03x | 3.97x | 15.88x | 0.38x | 4.35x |
| Price / BookPrice ÷ Book value/share | 8.87x | 1.65x | 9.10x | 0.55x | 4.87x |
| Price / FCFMarket cap ÷ FCF | 72.45x | 8.63x | 64.18x | 11.17x | 25.53x |
Profitability & Efficiency
ISRG leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 47.6% return on equity — every $100 of shareholder capital generates $48 in annual profit, vs $-51 for PRGO. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), PEN scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.3% | +47.6% | +16.9% | -50.7% | +15.0% |
| ROA (TTM)Return on assets | +9.6% | +32.4% | +14.8% | -19.8% | +6.9% |
| ROICReturn on invested capital | +11.3% | +14.2% | +15.0% | +3.7% | +11.4% |
| ROCEReturn on capital employed | +12.5% | +12.4% | +16.5% | +4.3% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.15x | 0.23x | 0.02x | 1.35x | 0.66x |
| Net DebtTotal debt minus cash | $33M | -$282M | -$3.1B | $3.4B | $10.8B |
| Cash & Equiv.Liquid assets | $187M | $551M | $3.4B | $532M | $4.0B |
| Total DebtShort + long-term debt | $220M | $269M | $303M | $4.0B | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | 304.65x | 63.45x | — | -7.20x | 6.72x |
Total Returns (Dividends Reinvested)
INVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,448 today (with dividends reinvested), compared to $3,969 for PRGO. Over the past 12 months, INVA leads with a +23.2% total return vs PRGO's -52.0%. The 3-year compound annual growth rate (CAGR) favors INVA at 25.1% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.1% | +15.2% | -19.9% | -13.6% | -17.8% |
| 1-Year ReturnPast 12 months | +11.6% | +23.2% | -16.4% | -52.0% | -24.5% |
| 3-Year ReturnCumulative with dividends | +3.7% | +96.0% | +48.5% | -58.1% | +2.4% |
| 5-Year ReturnCumulative with dividends | +22.3% | +94.5% | +61.7% | -60.3% | +17.5% |
| 10-Year ReturnCumulative with dividends | +501.4% | +95.6% | +549.2% | -77.7% | +179.2% |
| CAGR (3Y)Annualised 3-year return | +1.2% | +25.1% | +14.1% | -25.2% | +0.8% |
Risk & Volatility
INVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.11 beta — it tends to amplify market swings less than PRGO's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 91.0% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.23x | 0.11x | 1.00x | 1.21x | 0.52x |
| 52-Week HighHighest price in past year | $362.41 | $25.15 | $603.88 | $28.44 | $404.87 |
| 52-Week LowLowest price in past year | $221.26 | $16.52 | $427.84 | $9.23 | $284.97 |
| % of 52W HighCurrent price vs 52-week peak | +88.9% | +91.0% | +74.5% | +41.2% | +70.5% |
| RSI (14)Momentum oscillator 0–100 | 38.1 | 44.7 | 43.6 | 53.1 | 26.6 |
| Avg Volume (50D)Average daily shares traded | 533K | 604K | 1.8M | 3.3M | 2.1M |
Analyst Outlook
Evenly matched — PRGO and SYK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PEN as "Hold", INVA as "Buy", ISRG as "Buy", PRGO as "Hold", SYK as "Buy". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 14.8% for PEN (target: $370). For income investors, PRGO offers the higher dividend yield at 9.82% vs SYK's 1.18%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $369.83 | $40.00 | $622.60 | $36.20 | $389.62 |
| # AnalystsCovering analysts | 22 | 10 | 55 | 36 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% | +1.2% |
| Dividend StreakConsecutive years of raises | — | 0 | — | 10 | 34 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% | +1.4% | 0.0% | 0.0% |
INVA leads in 3 of 6 categories (Income & Cash Flow, Total Returns). PRGO leads in 1 (Valuation Metrics). 1 tied.
PEN vs INVA vs ISRG vs PRGO vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PEN or INVA or ISRG or PRGO or SYK a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PEN or INVA or ISRG or PRGO or SYK?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus Penumbra, Inc. at 71. 3x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 71x versus Intuitive Surgical, Inc. 's 1. 99x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PEN or INVA or ISRG or PRGO or SYK?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 5%, compared to -60. 3% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PEN or INVA or ISRG or PRGO or SYK?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 11β versus Perrigo Company plc's 1. 21β — meaning PRGO is approximately 968% more volatile than INVA relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — PEN or INVA or ISRG or PRGO or SYK?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Penumbra, Inc. grew EPS 1156% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PEN leads at 18. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PEN or INVA or ISRG or PRGO or SYK?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 8. 1% for PRGO. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PEN or INVA or ISRG or PRGO or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 71x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 5x forward P/E versus 65. 8x for Penumbra, Inc. — 60. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.
08Which pays a better dividend — PEN or INVA or ISRG or PRGO or SYK?
In this comparison, PRGO (9.
8% yield), SYK (1. 2% yield) pay a dividend. PEN, INVA, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is PEN or INVA or ISRG or PRGO or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, PRGO: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PEN and INVA and ISRG and PRGO and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PEN is a mid-cap high-growth stock; INVA is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; PRGO is a small-cap income-oriented stock; SYK is a mid-cap quality compounder stock. PRGO, SYK pay a dividend while PEN, INVA, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.